These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 9773099

  • 1. [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
    Rascol O, Brefel-Courbon C, Blin O.
    Therapie; 1998; 53(1):43-8. PubMed ID: 9773099
    [Abstract] [Full Text] [Related]

  • 2. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 3. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 4. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 5. [Physiopathology of the dyskinesias induced by L-dopa].
    Grandas F, López-Ariztegui N.
    Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
    [Abstract] [Full Text] [Related]

  • 6. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F, Marconi S.
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [Abstract] [Full Text] [Related]

  • 7. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M, Riederer P.
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [Abstract] [Full Text] [Related]

  • 8. Opioids and motor complications in Parkinson's disease.
    Samadi P, Bédard PJ, Rouillard C.
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [Abstract] [Full Text] [Related]

  • 9. [Dyskinesia caused by L-DOPA].
    Derkinderen P, Vidailhet M.
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M, Usiello A, Carta M, Håkansson K, Fisone G, Cenci MA.
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [Abstract] [Full Text] [Related]

  • 11. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ.
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [Abstract] [Full Text] [Related]

  • 12. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Carta M, Carlsson T, Kirik D, Björklund A.
    Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
    [Abstract] [Full Text] [Related]

  • 13. Levodopa in the early treatment of Parkinson's disease.
    Murata M.
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R, Lees AJ.
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [Abstract] [Full Text] [Related]

  • 17. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 18. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.